Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
50%
Ph phase_3
2
50%

Phase Distribution

2

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (50.0%)
Phase 32 (50.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

NCT05305547
completedphase_3

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

NCT05897541
completedphase_1

A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants

NCT05409911
completedphase_1

A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants

NCT05363215

Clinical Trials (4)

Showing 4 of 4 trials
NCT05305547Phase 3

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

Completed
NCT05897541Phase 3

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

Completed
NCT05409911Phase 1

A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants

Completed
NCT05363215Phase 1

A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4